In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 200 of 342

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]	Technology appraisal guidance	11 March 2026
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]	Technology appraisal guidance	TBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]	Technology appraisal guidance	TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance	TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863	Technology appraisal guidance	10 July 2026
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance	6 January 2027
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]	Technology appraisal guidance	TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]	Technology appraisal guidance	TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]	Technology appraisal guidance	2 December 2026
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance	TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Technology appraisal guidance	TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]	Technology appraisal guidance	TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]	Technology appraisal guidance	TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]	Technology appraisal guidance	TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]	Technology appraisal guidance	TBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]	Technology appraisal guidance	28 September 2016
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237	Technology appraisal guidance	6 August 2026
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance	TBC
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]	Technology appraisal guidance	7 May 2026
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]	Technology appraisal guidance	TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance	TBC
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	TBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446	Technology appraisal guidance	25 September 2026
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance	TBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	TBC
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]	Technology appraisal guidance	TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]	Technology appraisal guidance	14 January 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024

Results per page

10
25
50
All